Video

Dr. Yorio on Treatment Options for Patients With Rare Mutations in Metastatic Lung Cancer

Author(s):

Jeff Yorio, MD, discusses treatment options for patients with rare mutations in metastatic lung cancer.

Jeff Yorio, MD, medical oncologist, Texas Oncology, discusses treatment options for patients with rare mutations in metastatic lung cancer.

The identification of rare molecular aberrations in metastatic lung cancer has increased the utility of up-front genetic testing, explains Yorio. Moreover, targeted therapy may be an option for patients with specific mutations.

Clinical trials may be an alternative for patients with an alteration for which there is no available treatment strategy; however, it can be difficult to enroll patients with rare alterations like MET exon 14 skipping mutations in large clinical studies, says Yorio.

Pooling patients with a rare abnormality is important to demonstrate the efficacy of an investigational drug and develop more efficient models to treat patients with potentially actionable mutations, concludes Yorio.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity